<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493827</url>
  </required_header>
  <id_info>
    <org_study_id>2019PI224</org_study_id>
    <nct_id>NCT04493827</nct_id>
  </id_info>
  <brief_title>Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center</brief_title>
  <official_title>Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent discovery of oncogenic drivers has revolutionized the management of advanced lung&#xD;
      cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily&#xD;
      tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a&#xD;
      statistically significative difference for smoking habits. This region shows a higher&#xD;
      incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other&#xD;
      French regions. The objectives of our studie were to estimate the distribution of oncogenic&#xD;
      drivers and analyse their prognostic impacts in the Nancy University Hospital Center&#xD;
      metastatic lung adenocarcinoma's population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>over a period of 5 years (Day 0 = anatomopathological diagnosis)</time_frame>
    <description>Time (in months) from anatomopathological diagnosis to death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>over a period of 5 years (Day 0 = anatomopathological diagnosis)</time_frame>
    <description>Time (in months) from anatomopathological diagnosis to progression of the disease assessed by RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma</measure>
    <time_frame>At base line (Day 0 = anatomopathological diagnosis)</time_frame>
    <description>Distribution in percentage of main oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2), assessed by Sanger sequencing or FISH method in histological samples from metastatic lung adenocarcinomas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution in percentage of metastasis sites according oncogenic drivers</measure>
    <time_frame>At baseline (Day 0 = anatomopathological diagnosis)</time_frame>
    <description>Distribution in percentage of metastatic sites assessed by CT-scan for metastatic lung adenocarcinomas according oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2)</description>
  </secondary_outcome>
  <enrollment type="Actual">114</enrollment>
  <condition>Adenocarcinoma of Lung Stage IV</condition>
  <condition>Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic lung adenocarcinoma diagnosed between 2012 and 2014 with a medical&#xD;
        follow-up entirely done in Nancy Central Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lung adenocarcinoma&#xD;
&#xD;
          -  Patients diagnosed at a metastatic stage&#xD;
&#xD;
          -  Patient who benefited an oncogenic driver research on their histologic samples&#xD;
&#xD;
          -  Medical follow-up entirely done in Nancy Central Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with double histology&#xD;
&#xD;
          -  Synchronous cancer&#xD;
&#xD;
          -  Patients with surgical care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelica Tiotiu</last_name>
    <role>Study Director</role>
    <affiliation>Nancy Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Meurthe Et Moselle</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

